ESR2 and neoplasm: Finally, we used anti-CD8 Ab to deplete CD8 T cells during Erb-sumIL2 treatment, the depletion of CD8+ T cells greatly abolished the therapeutic effects, but Erb-sumIL2 could still partially control tumor growth (Fig. 3d).